BlackBarn Capital Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

BlackBarn Capital Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.5M	Sell	1,300,000 -350,000	-21%	-$4.8M	1.9%	15
2026 Q1	$20.5M	Buy	1,650,000 +80,000	+5%	+$1.07M	1.65%	14
2025 Q4	$19.8M	Sell	1,570,000 -619,452	-28%	-$7.09M	1.3%	11
2025 Q3	$21.9M	Sell	2,189,452 -1,257,118	-36%	-$11.3M	1.57%	9
2025 Q2	$27.9M	Buy	3,446,570 +564,916	+20%	+$4.26M	1.6%	5
2025 Q1	$24.1M	Buy	2,881,654 +31,654	+1%	+$264K	1.54%	7
2024 Q4	$22.6M	Buy	2,850,000 +438,388	+18%	+$3.68M	1.24%	7
2024 Q3	$20.1M	Buy	2,411,612 +411,612	+21%	+$3.22M	2.64%	5
2024 Q2	$12.7M	Buy	2,000,000 +586,703	+42%	+$3.72M	1.13%	7
2024 Q1	$8.56M	Buy	+1,413,297	New	+$7.97M	4.84%	10

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

BlackBarn Capital Partners's AMRX Position: Q2 2026 in Review

BlackBarn Capital Partners reduced its Amneal Pharmaceuticals (AMRX) stake by 21% in Q2 2026, selling an estimated $4.8M and leaving 1,300,000 shares worth $22.5M. The position accounts for 1.9% of the portfolio, ranked #15.

BlackBarn Capital Partners first reported a position in AMRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $27.9M in Q2 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

BlackBarn Capital Partners held 1,300,000 shares of Amneal Pharmaceuticals worth $22.5M as of Q2 2026.
BlackBarn Capital Partners sold 350,000 Amneal Pharmaceuticals shares in Q2 2026, an estimated $4.8M.
Amneal Pharmaceuticals made up 1.9% of BlackBarn Capital Partners's portfolio in Q2 2026, its #15 holding.
BlackBarn Capital Partners first reported a position in Amneal Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
BlackBarn Capital Partners's Amneal Pharmaceuticals position peaked at $27.9M in Q2 2025.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on BlackBarn Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.